Krystal Biotech (KRYS) Amortizatization of Intangibles (2019 - 2026)
Krystal Biotech recorded quarterly Amortizatization of Intangibles of $204000.0 in Q1 2026, up 2.0% quarter-over-quarter from $200000.0 in Q4 2025, and down 8.93% year-over-year from $224000.0 in Q1 2025.
Krystal Biotech's Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $204000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 8.93% year-over-year to $204000.0; the TTM figure through Mar 2026 stood at $807000.0 (up 2.28% YoY), while the FY2025 annual figure was $827000.0, up 10.71% from the prior year.
- Amortizatization of Intangibles came in at $204000.0 for Q1 2026 at Krystal Biotech, up from $200000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $233000.0 in Q4 2023 to a low of $182000.0 in Q1 2024.
- A 4-year average of $206307.7 and a median of $204000.0 in 2026 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles decreased 18.26% in 2024 and gained 23.08% in 2025, its largest moves.
- Krystal Biotech's Amortizatization of Intangibles stood at $233000.0 in 2023, then fell by 18.03% to $191000.0 in 2024, then gained by 4.71% to $200000.0 in 2025, then climbed by 2.0% to $204000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $204000.0, $200000.0, and $209000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Krystal Biotech | 9.05 Bn | 8.23 Bn | 110.03 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 204,000.00 |
| Mar 31, 2026 | 204,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Jun 30, 2025 | 194,000.00 |
| Jun 30, 2025 | 194,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | 191,000.00 |
| Dec 31, 2024 | 191,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 233,000.00 |
| Dec 31, 2023 | 233,000.00 |
| Sep 30, 2023 | 230,000.00 |
| Sep 30, 2023 | 230,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Mar 31, 2023 | 218,000.00 |
| Mar 31, 2023 | 218,000.00 |
| Mar 31, 2020 | 26,000.00 |
| Mar 31, 2020 | 26,000.00 |
| Dec 31, 2019 | 26,000.00 |
| Dec 31, 2019 | 26,000.00 |
| Sep 30, 2019 | 68,000.00 |
| Sep 30, 2019 | 68,000.00 |
| Jun 30, 2019 | 65,000.00 |
| Jun 30, 2019 | 65,000.00 |
| Mar 31, 2019 | 67,000.00 |
| Mar 31, 2019 | 67,000.00 |